ReNeuron Group plc

("ReNeuron" or the "Company")

Director Declaration

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that Iain Ross, Chairman, has advised the Company that Palla Pharma Limited (ASX:PAL), of which he is a Non-Executive Director, has entered into voluntary administration on 17 December 2021.

The ASX announcement can be viewed in full via the following link:

https://www.asxonline.com/public/notices/2021/December/1861.21.12.html 

This announcement is made in accordance with Rule 17 and schedule 2, paragraph (g) of the AIM Rules for Companies.

                                                                                                                ENDS

Contacts:

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa. 

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain.  The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com